ReSync Bio: Drug Discovery Data Automation Company Raises Funding
By Amit Chowdhry ● Sep 26, 2024
ReSync Bio, a scientific software provider accelerating preclinical R&D, announced its official launch and a funding round from Caffeinated Capital, Atria Ventures, and leading angel investors, including Ramsey Homsany, co-founder of Octant Bio. The company will use the funds to make key hires and commercialize its platform, which is now available for use by companies and academics.